A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
After watching this activity, participants should be better able to:
- Explain the role and importance of real-world evidence (RWE) in supporting clinical decision making
- Outline the key RWE related to the treatment of elderly and frail patients with multiple myeloma
- Discuss the management of elderly and frail patients with multiple myeloma in clinical practice
In this activity, Dr Faith Davies, a multiple myeloma expert, and Dr E Randolph Broun, a community oncologist and haematologist, discuss some of the real-world evidence relating to the treatment of elderly and frail patients with multiple myeloma and how it influences their clinical practice. The discussion of these themes is based on questions posed by healthcare professionals involved in the care of patients with multiple myeloma.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of haematologists and oncologists involved in the management of multiple myeloma.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Faith Davies discloses: Advisory board or panel fees from AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi and Takeda.
Dr E Randolph Broun discloses: Consultancy fees from Fresenius Kabi.
Rebecca Margaret Gonzalez-Winegar, PharmD, BCOP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact email@example.com.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 14 June 2022. Date credits expire: 14 June 2023.
If you have any questions regarding credit please contact firstname.lastname@example.org.
To obtain the CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?This activity is CE/CME accredited
Jorge Cortes: Ruxolitinib in myelofibrosis & rusfertide treatment in patients with phlebotomy-dependent polycythemia vera
Improving outcomes in multiple myeloma with new treatment targetsThis activity is CE/CME accredited
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
Myelodysplastic Syndromes – The Epigenetic Model for Drug Development?
The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors – What is New in the Battle of CML?
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!